Cargando…
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
IMPORTANCE: Initial approval for immune checkpoint inhibitors (ICIs) for treatment of advanced non–small cell lung cancer (NSCLC) was limited to patients with high levels of programmed cell death ligand 1 (PD-L1) expression. However, in the period after approval, it is not known how new evidence sup...
Autores principales: | Leapman, Michael S., Presley, Carolyn J., Zhu, Weiwei, Soulos, Pamela R., Adelson, Kerin B., Miksad, Rebecca A., Boffa, Daniel J., Gross, Cary P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280954/ https://www.ncbi.nlm.nih.gov/pubmed/32511721 http://dx.doi.org/10.1001/jamanetworkopen.2020.7205 |
Ejemplares similares
-
Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers
por: Cheng, En, et al.
Publicado: (2021) -
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021) -
Association of Socioeconomic Characteristics With Receipt of Pediatric Cochlear Implantations in California
por: Fujiwara, Rance J. T., et al.
Publicado: (2022) -
Drive Time and Receipt of Guideline-Recommended Screening, Diagnosis, and Treatment
por: Baldomero, Arianne K., et al.
Publicado: (2022) -
Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
por: Leapman, Michael S., et al.
Publicado: (2021)